Pembrolizumab plus denosumab produced a 31% ORR and 53% 6-month PFS rate in VEGFR-TKI-pretreated advanced clear cell renal cell carcinoma.
News|Articles|March 24, 2026
Early Intervention and Individualization Are Key to Improving Kidney Cancer Outcomes
Author(s)Kyle Doherty
Fact checked by: Caroline Seymour, Nicole Canfora Lupo
Neil Mendhiratta, MD, MS, and Toni K. Choueiri, MD, discuss the current and future treatment landscape of kidney cancer during Kidney Cancer Awareness Month.
Advertisement
Advertisement
Although the incidence of kidney cancer has stabilized after decades of increase with mortality rates on the decline, an emphasis on early intervention and treatment personalization is needed to maintain and build upon these improved outcomes for patients, according to Neil Mendhiratta, MD, MS.1
Related to this article
Early nivolumab responders sustained years-long treatment-free survival after treatment discontinuation.
Durable outcomes were reported standard-dose tivozanib monotherapy in second- and third-line metastatic RCC.
Darlifarnib plus cabozantinib showed durable responses and manageable safety in cabozantinib-naive advanced clear cell RCC.
The FDA approved iberdomide-based therapy for relapsed myeloma, rejected a neuroendocrine tumor therapy, and more.
Pankit Vachhani, MD, discusses the importance of hematocrit control in the management of polycythemia vera.
A new study suggests genomic newborn screening could identify children at risk for early cancers and enable earlier diagnosis and less toxic treatment.
The CLDN18.2/CD47 bispecific antibody spevatamig has received FDA fast track designation for advanced and metastatic biliary tract carcinoma.
Advertisement
Advertisement